Control Bionics (ASX:CBL) YoY EPS Growth: 0.00% (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Control Bionics YoY EPS Growth?

Control Bionics ASX:CBL -1.69% YoY EPS Growth is 0.00% as of Jun. 2026. The stock has 7 warning signs investors should review.

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Control Bionics's YoY EPS Growth for the quarter that ended in Jun. 2026 was 0.00%.

Control Bionics's Earnings per Share (Diluted) for the six months ended in Jun. 2026 was A$-0.01.

Control Bionics YoY EPS Growth Historical Data

* Premium members only.

The historical data trend for Control Bionics's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Control Bionics YoY EPS Growth Chart

Control Bionics Annual Data
Trend Jun20 Jun21 Jun22 Jun23 Jun24 Jun25 Jun26
YoY EPS Growth
Get a 7-Day Free Trial -26.00 12.70 34.55 36.11 13.04

Control Bionics Semi-Annual Data
Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25 Jun26
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 30.77 30.00 50.00 21.43 0.00

Control Bionics YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Control Bionics's YoY EPS Growth for the fiscal year that ended in Jun. 2026 is calculated as:

YoY EPS Growth (A: Jun. 2026 )
=(Earnings per Share (Diluted) (A: Jun. 2026 )-Earnings per Share (Diluted) (A: Jun. 2025 ))/ | Earnings per Share (Diluted) (A: Jun. 2025 ) |
=(-0.02--0.023)/ | -0.023 |
=13.04 %

Control Bionics's YoY EPS Growth for the quarter that ended in Jun. 2026 is calculated as:

YoY EPS Growth (Q: Jun. 2026 )
=(Earnings per Share (Diluted) (Q: Jun. 2026 )-Earnings per Share (Diluted) (Q: Jun. 2025 )) / | Earnings per Share (Diluted) (Q: Jun. 2025 )) |
=(-0.009--0.009)/ | -0.009 |
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about YoY EPS Growth →
What does a YoY EPS Growth of 0.00% mean?
Control Bionics (ASX:CBL) has a YoY EPS Growth of 0.00% as of Jun. 2026. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Control Bionics and its competitors.
Is Control Bionics' YoY EPS Growth too high?
Control Bionics' current YoY EPS Growth is 0.00%.
How does Control Bionics' YoY EPS Growth compare to ABT and SYK?
Control Bionics' YoY EPS Growth of 0.00% can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good YoY EPS Growth for a Medical Devices & Instruments company?
A good YoY EPS Growth depends on the Medical Devices & Instruments industry context. However, YoY EPS Growth should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high YoY EPS Growth mean?
A high YoY EPS Growth can signal that a stock is expensive relative to its fundamentals. YoY EPS Growth is the percentage change of EPS over the past 12-month. View historical data for Control Bionics and its competitors. Control Bionics's current YoY EPS Growth is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Control Bionics stock overvalued right now?
Based on GuruFocus' analysis, Control Bionics (ASX:CBL) is currently considered Significantly Overvalued. The stock's GF Value™ is A$0.02, compared to a current price of A$0.06 — trading 190% above its estimated fair value. The current YoY EPS Growth is 0.00%. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is YoY EPS Growth calculated?
YoY EPS Growth is calculated from a company's financial statements. For Control Bionics (ASX:CBL), the current YoY EPS Growth is 0.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Control Bionics Business Description

Address 11-13 Pearson Street, Level 4, Cremorne, VIC, AUS, 3121
Control Bionics Ltd is engaged in the healthcare device business. It is involved in developing, commercializing, and selling assistive communications technology systems within the disability sector. Its core systems include NeuroNode Trilogy and NeuroNode3. These systems allow people with speech and movement difficulties to control a computer for speech generation, electronic communications, entertainment, and external control of other devices. Geographically, it derives a majority of revenue from North America and has its presence in Australia as well.